{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:04:54Z","timestamp":1790802294218,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117033","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:38:49Z","timestamp":1789054729000},"page":"117033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma"],"prefix":"10.1016","volume":"247","author":[{"given":"Anna","family":"Fosfuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Orsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3374-4220","authenticated-orcid":false,"given":"Catia","family":"Carconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Procaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1802-5671","authenticated-orcid":false,"given":"Ilario Giovanni","family":"Rapposelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Bencardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Macchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0799-0209","authenticated-orcid":false,"given":"Nicole","family":"Liscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5113-2793","authenticated-orcid":false,"given":"Luigi Carmine","family":"Leta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8535-119X","authenticated-orcid":false,"given":"Barbara","family":"Merelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sperti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8118-7342","authenticated-orcid":false,"given":"Silvia","family":"Bozzarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-9494","authenticated-orcid":false,"given":"Mariacristina","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4619-7091","authenticated-orcid":false,"given":"Emiliano","family":"Tamburini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Malleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7474-0325","authenticated-orcid":false,"given":"Francesca","family":"Aleotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Capurso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Giorgio","family":"Arcidiacono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9654-7243","authenticated-orcid":false,"given":"Massimo","family":"Falconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6463-0293","authenticated-orcid":false,"given":"Michele","family":"Reni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.117033_bib1","article-title":"Advances in the management of pancreatic cancer","volume":"383","author":"Del Chiaro","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2026.117033_bib2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.21037\/jgo.2016.01.03","article-title":"Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial","volume":"7","author":"Scheithauer","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ejca.2026.117033_bib3","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.1990.8.12.1935","article-title":"The calculation of received dose intensity","volume":"8","author":"Hryniuk","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117033_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115470","article-title":"The relative dose intensity of first-line FOLFOXIRI and FOLFOX\/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: a pooled analysis of TRIBE and TRIBE2 studies","volume":"222","author":"Moretto","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117033_bib5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clbc.2018.02.003","article-title":"Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer","volume":"18","author":"Denduluri","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ejca.2026.117033_bib6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.12.019","article-title":"Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer","volume":"66","author":"Luciani","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2026.117033_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.critrevonc.2014.10.006","article-title":"A review of relative dose intensity and survival in patients with metastatic solid tumors","volume":"93","author":"Havrilesky","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2026.117033_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13822","article-title":"Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis","volume":"26","author":"Nielson","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.117033_bib9","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer a randomized clinical trial","author":"Conroy","year":"2022","journal-title":"Vis Abstr Suppl Content"},{"key":"10.1016\/j.ejca.2026.117033_bib10","doi-asserted-by":"crossref","unstructured":"Turner K.M., Delman A.M., Vaysburg D.M., Kharofa J.R., Smith M.T., Choe K.A., et al. Systemic Therapy for Resected Pancreatic Adenocarcinoma: How Much is Enough? 2022. https:\/\/doi.org\/10.1245\/s10434-022-11363-0.","DOI":"10.1245\/s10434-022-11363-0"},{"key":"10.1016\/j.ejca.2026.117033_bib11","article-title":"Effect of dose adjustments on overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX: a post hoc analysis of NAPOLI 3","volume":"43","author":"Patel","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117033_bib12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/CCM.0000000000004676","article-title":"Standardized care is better than individualized care for the majority of critically ill patients","volume":"49","author":"Sevransky","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ejca.2026.117033_bib13","article-title":"Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life","author":"Reni","year":"2024","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ejca.2026.117033_bib14","article-title":"Preoperative mFOLFIRINOX versus PAXG for stage I\u2013III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2\u2009\u00d7\u20092 factorial phase 3 trial","volume":"0","author":"Reni","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.117033_bib15","article-title":"Biochemical, radiographic, or pathologic response to neoadjuvant chemotherapy in resected pancreatic cancer: which is best?","author":"Ahmad","year":"2024","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2026.117033_bib16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.pan.2025.02.007","article-title":"Early response evaluation using CT and CA 19-9 in patients with pancreatic cancer of all stages undergoing first-line FOLFIRINOX treatment","volume":"25","author":"Kim","year":"2025","journal-title":"Pancreatology"},{"key":"10.1016\/j.ejca.2026.117033_bib17","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1093\/annonc\/mdx495","article-title":"Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma","volume":"28","author":"Reni","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117033_bib18","doi-asserted-by":"crossref","first-page":"11875","DOI":"10.3390\/ijms262411875","article-title":"Platinum meets pyridine: affinity studies of pyridinecarboxylic acids and nicotinamide for platinum\u2014based drugs","volume":"26","author":"Szefler","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2026.117033_bib19","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA - J Am Med Assoc"},{"key":"10.1016\/j.ejca.2026.117033_bib20","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.pan.2024.10.002","article-title":"Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI survey","volume":"24","author":"Reni","year":"2024","journal-title":"Pancreatology"},{"key":"10.1016\/j.ejca.2026.117033_bib21","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2026.117033_bib22","article-title":"Pembrolizumab and olaparib (POLAR) maintenance therapy in metastatic pancreatic cancer with or without homologous repair deficiency: a biomarker selected phase II trial","author":"Park","year":"2025","journal-title":"Res Sq"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:33:43Z","timestamp":1790800423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926008142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"alternative-id":["S0959804926008142"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117033","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117033"}}